Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 20/20 | 0.70 |
| ▸ | SSTR1 | P30872 | 2/20 | 0.54 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.43 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.43 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20029381 | 0.89 | SSTR4 (0.68) | SSTR4SSTR1SSTR2SSTR3SSTR5 | |
| SCHEMBL19724681 | 0.85 | SSTR4 (0.71) | SSTR4SSTR1SSTR2SSTR3SSTR5 | |
| SCHEMBL16255859 | 0.85 | SSTR4 (0.71) | SSTR4SSTR1SSTR2SSTR3SSTR5 | |
| SCHEMBL19724545 | 0.83 | SSTR4 (1.00) | SSTR4SSTR1SSTR3 | |
| SCHEMBL16256037 | 0.83 | SSTR4 (1.00) | SSTR4SSTR1SSTR3 | |
| SCHEMBL20029354 | 0.80 | SSTR4 (0.70) | SSTR4SSTR1SSTR2SSTR3SSTR5 | |
| SCHEMBL20029305 | 0.80 | SSTR4 (0.68) | SSTR4SSTR1SSTR2SSTR3SSTR5 | |
| SCHEMBL20029348 | 0.80 | SSTR4 (0.69) | SSTR4SSTR1SSTR2SSTR3SSTR5 | |
| SCHEMBL20029351 | 0.80 | SSTR4 (0.69) | SSTR4SSTR1SSTR2SSTR3SSTR5 | |
| SCHEMBL20029222 | 0.80 | SSTR4 (0.68) | SSTR4SSTR1SSTR2SSTR3SSTR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10166214-B2 | Somatostatin receptor subtype 4 (SSTR4) agonists | CENTREXION THERAPEUTICS CORPORATION (US) | 2019-01-01 | — | — | US | disclosed |
| US-20180092880-A1 | SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | ANKURA TRUST COMPANY, LLC, AS ADMINISTRATIVE AND COLLATERAL AGENT | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180092880-A1 | SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | SSTR4, SSTR3, SSTR1 | SSTR4 1/4885SSTR1 3/4885SSTR2 5/4885 |
| US-10166214-B2 | Somatostatin receptor subtype 4 (SSTR4) agonists | SSTR4, SSTR3, SSTR1 | SSTR4 1/4885SSTR1 3/4885SSTR2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.